Cannabinoids in Late-Onset Alzheimer's Disease
Cannabinoids in Late-Onset Alzheimer's Disease
复制标题
DOI：
10.1002/cpt.117
复制
发表时间：
2015-06-01
影响因子：
6.7
通讯作者：
Rikkert, M. G. M. Olde
中科院分区：
文献类型：
--
作者：
Ahmed, A. I. A.;van der Marck, M. A.;Rikkert, M. G. M. Olde
鉴于迟发性阿尔茨海默病（LOAD）缺乏有效的治疗方法，以及对患者、家庭、卫生保健系统和经济造成的巨大负担，寻找有效的治疗方法是最高的医疗优先事项之一。过去几年，人们对大麻素（大麻植物的生物活性成分）的医疗用途越来越感兴趣，包括治疗老年人常见的LOAD和其他身体状况。几项体外和体内研究表明，大麻素可以减少氧化应激、神经炎症、淀粉样斑块和神经原纤维缠结的形成，这是LOAD的关键标志。此外，在基于人群的研究中，大麻素减少了痴呆症相关症状（例如，行为障碍）。目前的文章概述了大麻素在治疗老年人LOAD和相关神经精神症状方面的潜力。我们还讨论了大麻素类药物在老年痴呆患者中的疗效、安全性和药代动力学。
Given the lack of effective treatments for late-onset Alzheimer's disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment of LOAD and other physical conditions that are common in older people. Several in vitro and in vivo studies have demonstrated that cannabinoids can reduce oxidative stress, neuroinflammation, and the formation of amyloid plaques and neurofibrillary tangles, the key hallmarks of LOAD. In addition, in population-based studies, cannabinoids reduced dementia-related symptoms (e.g., behavioral disturbances). The current article provides an overview of the potential of cannabinoids in the treatment of LOAD and related neuropsychiatric symptoms in older people. We also discuss the efficacy, safety, and pharmacokinetics of cannabinoid-based drugs in older people with dementia.